4.7 Article

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis

Alasdair J. Coles et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Review Clinical Neurology

Sporadic inclusion body myositis - diagnosis, pathogenesis and therapeutic strategies

Marinos C. Dalakas

NATURE CLINICAL PRACTICE NEUROLOGY (2006)

Article Clinical Neurology

The window of therapeutic opportunity in multiple sclerosis

AJ Coles et al.

JOURNAL OF NEUROLOGY (2006)

Article Immunology

Inclusion body myositis:: Clonal expansions of muscle-infiltrating T cells persist over time

K Müntzing et al.

SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2003)

Review Oncology

Campath-1H monoclonal antibody therapy

JM Flynn et al.

CURRENT OPINION IN ONCOLOGY (2000)